tak-981
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2018 (NCT03648372)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Small ubiquitin-related modifier 1INHIBITOR
SUMO1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1sc(C(=O)c2cncnc2N[C@@H]2CC[C@H](COS(N)(=O)=O)[C@H]2O)cc1[C@@H]1NCCc2ccc(Cl)cc21- Mol. weight
- 578.12 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095044 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05976334 | Phase 1 | Nov 14, 2023 | Takeda |
| NCT04776018 | Phase 1/Phase 2 (Phase 2) | Apr 20, 2021 | Takeda |
| NCT04381650 | Phase 1/Phase 2 (Phase 2) | May 31, 2020 | Takeda |
| NCT04065555 | Early Phase 1 (Phase 1) | Dec 31, 2019 | Presage Biosciences, Takeda |
| NCT04074330 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2019 | Millennium Pharmaceuticals |
| NCT03648372 | Phase 1 | Sep 28, 2018 | Millennium Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 4 | 3 | 2 | 2019 |
| Millennium Pharmaceuticals | For profit | 2 | 2 | 2 | 2018 |
| Presage Biosciences | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1